International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 068-072
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
GEMCITABINE TREATMENT IN PATIENTS WITH ANTHRACYCLINE- AND TAXANE- PRETREATED METASTATIC BREAST CANCER
Veliddin C. SEZGİN1, Bülent KARABULUT1, Rüçhan USLU1, Ulus A. ŞANLI1, Erdem GÖKER1
Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, İZMİR
Keywords: Metastatic breast cancer, Gemcitabine, Anthracycline, Taxane
The efficacy and tolerability of gemcitabine were studied in 15 patients with anthracycline- and taxane- pretreated metastatic breast cancer. Gemcitabine was administered as a 30-minute intravenous 1000 mg/m2 infusion once a week for 3 weeks followed by a 1-week rest every 4 weeks. The mean number of completed cycles was 4 (range: 1-12). The overall response rate (ORR) was 7% with a median duration response of 12 months. Median time to progression was 5 months (%95 CI: 3,56-6,44). Median duration of survival was 20 months (%95 CI: 11,70-40,30). Gemcitabine was well tolerated in previously pretreated metastatic breast cancer. In view of its toxicity profile, and its novel mechanism of action, gemcitabine warrants further evaluation in breast cancer patients, both as a single agent and in combination treatment schedules.
Veliddin C. SEZGİN1, Bülent KARABULUT1, Rüçhan USLU1, Ulus A. ŞANLI1, Erdem GÖKER1
Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, İZMİR
Keywords: Metastatic breast cancer, Gemcitabine, Anthracycline, Taxane
The efficacy and tolerability of gemcitabine were studied in 15 patients with anthracycline- and taxane- pretreated metastatic breast cancer. Gemcitabine was administered as a 30-minute intravenous 1000 mg/m2 infusion once a week for 3 weeks followed by a 1-week rest every 4 weeks. The mean number of completed cycles was 4 (range: 1-12). The overall response rate (ORR) was 7% with a median duration response of 12 months. Median time to progression was 5 months (%95 CI: 3,56-6,44). Median duration of survival was 20 months (%95 CI: 11,70-40,30). Gemcitabine was well tolerated in previously pretreated metastatic breast cancer. In view of its toxicity profile, and its novel mechanism of action, gemcitabine warrants further evaluation in breast cancer patients, both as a single agent and in combination treatment schedules.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |